Foresight Diagnostics' Insights on Lymphoma MRD Analysis at ASH Annual Meeting Discover the groundbreaking presentations Foresight Diagnostics will showcase at the ASH Annual Meeting, unveiling new MRD analysis techniques.

Foresight Diagnostics' Insights on Lymphoma MRD Analysis at ASH Annual Meeting #USA #Orlando #ASH_Annual_Meeting #Foresight_Diagnostics #PhasED-Seq

Foresight Diagnostics Partners with Roche for Innovative Cancer Technology Licensing Foresight Diagnostics and Roche have signed a licensing agreement for the PhasED-Seq™ technology, enhancing diagnostics for Non-Hodgkin's Lymphoma.

Foresight Diagnostics Partners with Roche for Innovative Cancer Technology Licensing #USA #Roche #Boulder #Foresight_Diagnostics #PhasED-Seq

Foresight Diagnostics Unveils CLARITY™ MRD Assay Data at Major Hematology Conferences Foresight Diagnostics is set to present innovative data on its CLARITY™ MRD assay at the 2025 EHA Congress and ICML, showcasing new advancements in lymphoma treatment.

Foresight Diagnostics Unveils CLARITY™ MRD Assay Data at Major Hematology Conferences #United_States #Hematology #Boulder #Foresight_Diagnostics #CLARITY_MRD

Foresight Diagnostics Partners with QIAGEN to Enhance Diagnostic Kits for Lymphoma Treatments Foresight Diagnostics has formed a strategic alliance with QIAGEN to craft advanced diagnostic kits aimed at lymphoma and blood cancer detection.

Foresight Diagnostics Partners with QIAGEN to Enhance Diagnostic Kits for Lymphoma Treatments #USA #Boulder,_Colorado #Foresight_Diagnostics #QIAGEN #CLARITY_assay

Foresight Diagnostics Shares Validated Data on MRD Assay at ASCO 2025 Foresight Diagnostics announces independent validation of its CLARITY MRD assay in frontline DLBCL patients, showcasing significant prognostic insights at the 2025 ASCO Annual Meeting.

Foresight Diagnostics Shares Validated Data on MRD Assay at ASCO 2025 #United_States #Chicago #DLBCL #Foresight_Diagnostics #CLARITY_MRD

Foresight Diagnostics to Showcase Next-Gen MRD Detection Data at ASCO 2025 Annual Meeting Foresight Diagnostics will present groundbreaking data on ultra-sensitive minimal residual disease detection during the ASCO 2025 meeting, targeting improved cancer therapy outcomes.

Foresight Diagnostics to Showcase Next-Gen MRD Detection Data at ASCO 2025 Annual Meeting #United_States #Chicago #ASCO_2025 #Foresight_Diagnostics #MRD_Detection

Foresight Diagnostics Initiates PRECISE-HL Trial for Tailored cHL Treatments with ctDNA Technology Foresight Diagnostics has launched the PRECISE-HL trial to evaluate ctDNA-based de-escalation of therapy for classical Hodgkin lymphoma patients showing early response, potentially transforming treatment protocols.

Foresight Diagnostics Initiates PRECISE-HL Trial for Tailored cHL Treatments with ctDNA Technology #USA #Boulder #Foresight_Diagnostics #Hodgkin_Lymphoma #ctDNA

Foresight Diagnostics Partners with Allogene to Enhance Global MRD Detection Efforts Foresight Diagnostics has deepened its collaboration with Allogene Therapeutics to advance minimal residual disease detection developments across multiple countries outside the U.S.

Foresight Diagnostics Partners with Allogene to Enhance Global MRD Detection Efforts #USA #Boulder #Foresight_Diagnostics #Allogene_Therapeutics #MRD_Detection